The study included all free-living persons in each sampled household aged ≥ 65 years. Among the 834 participants, a RAS of ≥60% was identified in 6.8% (57/834) of participants. There was a significant association with increasing participant age, decreased HDL and increased systolic BP. After an 8-year period, 119 participants had a second RDS, which was technically satisfactory in 235 kidneys. At first examination, ARVD was present in 13 kidneys (5.5%). None of the subjects who had > 60% stenosis at baseline progressed to occlusion at the second study. New stenoses of ≥60% (‘incident’ stenoses) were identified in 9 kidneys (2.9%). By univariate analysis, the increase in diastolic

BP (P = 0.01) and decrease in renal size (P < 0.001) were significantly associated with incident stenoses. A healthy cohort effect from healthy participants and significantly less participant re-recruitment at follow up was collectively considered to have led LEE011 in vitro buy Talazoparib to an underestimation of RAS progression. The criteria for progression was change in PSV of greater than twice the standard deviation

of the predicted change in an age-matched cohort over a median follow-up period of 2 years. In the control group, 95% had some of the recognized risk factors for atherosclerosis. This could have resulted in a control cohort with a higher than expected rate of progression resulting in an underestimation of the progression in the study cohort. Other notable sources of bias were technological improvements in RDS using colour flow Doppler technology at the second follow up, inter-observer differences in reporting and a loss to follow up, with only a small number of patients who participated in the second study. Of the participants,

224 died after the initial study. There were little data on the cause of death, which was presumed by the authors to be mostly from cardiovascular causes. This could have selected participants with less severe vascular disease to complete the follow-up duplex, thus underestimating the progression rate. A number of studies suggest that ARVD can cause renal atrophy, and some risk factors for this have been identified. Caps et al. in their stenosis progression study discussed above examined the risk factors triclocarban and rate of atrophy of kidneys with a ≥60% stenosis on RDS.13 A total of 204 kidneys with such stenoses in 122 participants were followed for a mean of 33 months (range 5–72 months). They excluded kidneys with renal artery occlusion and prior intervention to their arteries as well as those with renal sizes < 8.5 cm. The baseline lengths were close to those expected in an age- and sex-matched population. A reduction of renal length greater than 1 cm occurred in 16.2% of the kidneys. The cumulative incidence of atrophy at 2 years was 5.5% for kidneys with normal baseline renal arteries, 11.7% in the ≤60% stenosis group and 20.8% in the ≥60% group. This association was significant (P = 0.009).